The fluxes of arginine and citruiline through plasma and the rate of conversion of labeled citrulline to arginine were estimated in two pilot studies (with a total of six adult subjects) and in a dietary study with five healthy young men. These latter subjects received an L-amino acid-based diet that was arginine-rich or arginine-free each for 6 days prior to conduct, on day 7, of an 8-hr (first 3 hr, fast; final 5 hr, fed) primed continuous intravenous infusion protocol using L- [guandno-93C]arginine, L-[5,5-2H2]citrulline, and L- [5,5,5-2H31leucine, as tracers. A pilot study indicated that citrulline flux was about 20% higher (P < 0.05) when determined with [ureido-13C]citrulline compared with [2H2Jcitruline, indicating recycling of the latter tracer. Mean citruilin fluxes were about 8-11 pmol kg'lhr'1 for the various metabolic/diet groups and did not differ significantly between fast and fed states or arginine-rich and arginine-free periods. Arginine fluxes (mean ± SD) were 60.2 ± 5.4 and 73.3 ± 13.9 jAmol kg"l hr'1 for fast and fed states during the arginine-rich period, respectively, and were significantly lowered (P < 0.05), by 20-40%, during the arginine-free period, especially for the fed state, where this was due largely to reduced entry of dietary arginine into plasma. The conversion of plasma citruiline to arginine approximated 5.5 ,umol*kg'l-hr-1 for the various groups and also was unaffected by arginine intake. Thus, endogenous arginine synthesis is not markedly responsive to acute alterations in arginine intake in healthy adults. We propose that argmine homeostasis is achieved largely via modulating arginine intake and/or the net rate of arginine degradation.
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The physiological needs by tissues and organs for arginine are met via the endogenous synthesis of arginine and/or arginine supplied by the diet. For the U.S. population the latter amounts to about 5.4 g daily per capita (1) . The rates of endogenous arginine synthesis in the immature rat (2, 3) , guinea pig (4), cat (5, 6) , dog (7) (8) (9) , chicken (10) , rabbit (11) , and pig (12) are not sufficient to support normal growth or maintain function, and so these species require a source of dietary arginine. The quantitative importance of dietary arginine for maintenance of physiologic function in humans is less clear (1, 13) . Under some pathological conditions, including liver disease and genetic errors of urea-cycle enzyme activity (13) (14) (15) , there is, or may be, a dietary need for arginine, implying inadequate rates of endogenous arginine synthesis. Few estimates ofthese rates in human subje,-ts and of their quantitative responses to nutritional, hormonal, and pathological factors are available. However, this information is needed to enhance our understanding of the relative importance ofendogenous and exogenous sources of arginine for maintaining arginine homeostasis and meeting its physiologic functions. The latter include, in addition to its role as a substrate for protein synthesis, its function as a precursor
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of nitric oxide (16) and of creatine and its participation as arginyl-tRNA in the process of ubiquitin-dependent protein degradation (17) . Therefore, we have begun to use stableisotope tracer techniques to explore, noninvasively, kinetic and regulatory aspects ofarginine metabolism in adult human subjects (18, 19) . Here we report results of a study in young men who were given for 7 days an arginine-rich diet and then, for another 7 days, an arginine-free diet. Our kinetic model involves L-[guanidino-13C]arginine and L- [5,5-2H2] citrulline as tracers, to estimate plasma arginine and citrulline fluxes as well as the rate of transfer of plasma citrulline into the arginine pool. From the present findings, and our recent studies (19) , we propose an integrative scheme of body arginine homeostasis and balance, which defines the metabolic basis for the conditional indispensability of dietary arginine under various pathophysiological conditions (1, 13, 14) . Pilot studies. Two subjects participated in an initial pilot experiment designed to help establish appropriate tracer doses of citrulline for our subsequent studies. They consumed for 2 days an adequate diet, and this was followed by a low-dose (0.29 ,umolkg-l hr-1) intravenous citrulline tracer infusion study on day 3 (see below). This experiment was repeated about 4 weeks later when we studied a higher (2.05 ,umol kg-l-hr-1) citrulline tracer dose, otherwise using similar experimental conditions. Four additional subjects took part in a second pilot study, which was conducted to assist interpretation of the isotopic data generated in our main, diet study (see below). These subjects consumed the adequate experimental diet (also see below) for 2 days and on day 3 they were given primed, simultaneous constant intravenous 7750 Applied Biological Sciences: Castillo et al.
MATERIALS AND METHODS
tracer infusions of L- [5,5-2H2] citrulline and L- [ureido- 13C]citrulline, each at known infusion rates of -0.98 ,mol kg-l hr-' Diet study. Five subjects participated in this investigation, which was concerned with the effects of arginine-rich (adequate) and arginine-free intakes on plasma arginine and citrulline kinetics. They consumed the arginine-rich diet for 6 days and on the morning of day 7 they received primed, constant intravenous tracer infusions of L- [guanidino- 13C]arginine, L- [5, 5, This tracer study was followed immediately by a second experimental diet period during which an arginine-free intake was given for 6 days. Again, on the morning of day 7, a second intravenous infusion protocol, also with the above tracers, was carried out.
Diets. For the pilot studies and during the first 7-day phase of the diet study, each subject received a complete L amino acid-based diet (formulated largely from the amino acid pattern of hen's egg white and whole egg powder), which provided the equivalent of about 1 g of "protein" (N x 6.25) per kg of body weight per day. The major energy source was provided in the form of protein-free wheat starch cookies. The composition of the diet has been described (19) .
For the diet experiment, each subject received for 7 days the arginine-rich L amino acid diet and during the next 7-day period, subjects received the same diet except that it was based on an isonitrogenous, arginine-free, L amino acid mixture formula, as described (19) . The daily intake, prior to the tracer infusion studies, was consumed as three separate meals at 0800, 1200, and 1700. Meals were prepared in the Clinical Research Center by the dietary staff.
Tracer Infusion Studies. The isotope infusion protocols for the pilot and dietary studies lasted 8 hr. For the first 3 hr, subjects remained in the postabsorptive state (fast state) following an overnight fast, which began at about 1900. This 3-hr phase was followed immediately by a 5-hr fed state during which subjects received small, equal meals at 30-or 60-min intervals (see below). Details of the procedures followed immediately before and during the infusion protocol have been described (19, 20) .
In the first pilot study, a relatively low priming dose (0.29 ,umolkg-1) was followed by a constant infusion (0.29 ,umol kg-l hr-1) of L- [5, [guanidino-13C]arginine was given as a primer dose (5.3 ,.molkg-1) and then as a constant infusion at 5.3 ,umol kg-l hr-1; a [2H3]leucine priming dose (4.2 ,umol kg) and continuous infusion (4.2 umol-kg-'hr-1) were given along with the citrulline and arginine tracers. Four weeks later this experiment was repeated in the same two subjects; on this occasion a larger tracer dose of citrulline (priming, 2.0 ,umol kg; continuous infusion, 2.0 ,umol.kg-l hr-1) was administered, together with [13C]arginine and [2H3]leucine tracers at the rates used for the first infusion during this pilot study.
For the second pilot study, two citrulline tracers (L- [5,5- 2H2]citrulline and L-[ureido-13C]citrulline) were given simultaneously, using priming doses of 0.98 j,mol kg-1 and continuous infusion rates of 0.98 ,mol kg-l1hr-1. In both pilot studies, beginning after 180 min of tracer infusion, subjects were given six equal meals at hourly intervals, with intake being equivalent to 1/12th ofthe total daily intake as provided by the experimental diet during the preceding diet period.
In the diet study, priming doses of L-[guanidino-13C]arginine (2.7 umol-kg-1), L- [5,5-2H2] citrulline (1.0 ,umol-kg-1) , and [2H3]leucine (4.0 p.mol kg-1) were administered over 3 min and then followed immediately by constant, known intravenous tracer infusions at rates of about 2.7, 1.0, and 4.0 ,0_molnkg'hr', respectively. After 180 min subjects were given small meals every 30 min for the next 5 hr, providing two-thirds of the previous day's amino acid and energy intake. Baseline blood samples were drawn before the tracers were given, and at 20-min intervals during the last hour of the initial 3-hr tracer period, and again frequently during the last 2 hr of the 5-hr fed phase. These were kept on ice until centrifuged. Plasma was removed and stored at -20°C prior to analysis. Infusates of tracers were prepared from sterile, pyrogen-free powders of high chemical purity and high isotopic enrichment. Tracers (-98% isotopic purity) were obtained from Tracer Technologies (Somerville, MA).
Analysis of Enrichment of Plasma Arginine, Cihtuflie, and Leucine. To determine the plasma isotopic enrichment of the 13C and 2H isotopologs of arginine and of citrulline, 200 Al of plasma was extracted essentially by the procedure of Adams (21). A methyl ester was first formed by using methanol and acetyl chloride, and N-trifluoroacetylation followed according to Nissim et al. (22) . Analysis of the methyl ester trifluoroacetyl derivatives was carried out by on-column injection onto an HP5890 series II gas chromatograph coupled to an HP5988A mass spectrometer (Hewlett-Packard). Selective ion monitoring of arginine and citrulline was conducted on the [M-20]-ions, using negative chemical ionization with methane as the reagent gas. These ions correspond to a loss of HF from the molecular ion. Selective ion monitoring was carried out at m/z 361, 362, and 363 for natural, 13C-labeled, and 2H-labeled citrulline, respectively, and at m/z 456, 457, and 458 for unlabeled, 13C-labeled, and 2H-labeled arginine, respectively.
Measurement of the plasma [2H3]leucine enrichments was determined in samples extracted as for arginine. A tertbutyldimethylsilyl derivative was prepared (23) and analyzed with a similar GC/MS system as for arginine and citrulline, using splitless injection and electron impact ionization. Selective ion monitoring was carried out at m/z 302 ([M-57]+) for unlabeled leucine and m/z 305 for the 2H-labeled species. All plasma samples were measured in duplicate and determined against calibration standards. Multiple linear regression was used to calculate the individual plasma isotope enrichments, which were expressed as mole fractions above the value determined from blood drawn prior to tracer administration.
Model of Citrulline and Arginine Kinetics. Plasma amino acid fluxes were calculated from the mean of the plasma isotopic enrichment values for the last 1 hr of the fast and last 2 hr of the fed phases of the tracer period by using steadystate isotope dilution equations, as for previous studies with leucine (18, 24) .
The rate of conversion of plasma citrulline to arginine (Qa) was determined essentially according to the tracer models of Clarke and Bier (25) and Thompson et al. (26) , used in these earlier cases for measurement of the conversion of labeled phenylalanine to tyrosine. Thus Evaluation of Data. Data were analyzed by a repeated measures procedure: subject by diet (arginine-free or arginine-rich) by condition (fast or fed) factorial. When a significant diet-condition interaction was observed, the analysis was repeated separately for each diet and conditions were compared. Plasma amino acid values were compared by a paired t test. P < 0.05 was considered statistically significant. Proc. Natl. Acad. Sci. USA 90 (1993) 
RESULTS AND DISCUSSION
To our knowledge, there have been no published estimates of plasma citrulline fluxes in healthy adults under defined dietary conditions. Hence, from the first pilot study we determined, as summarized in Table 1 , plasma fluxes of [5,5- 2H2dcitrulline to be 6-10 ,umol kg-l hr-1 during the fast and fed states in these two subjects. Based on these initial data we chose an intermediate citrulline tracer dose for use in the diet study; our purpose was to achieve an enrichment of plasma arginine in the range of about 0.01 mole fraction. The plasma fluxes of citrulline and arginine while subjects consumed the arginine-rich (adequate) or arginine-free diets are recorded in Table 2 . Citrulline fluxes were similar during the fed and fasted states and did not change during the 7-day period of consuming an arginine-free diet. Also, the rate of conversion of plasma citrulline to plasma arginine (QJ) was about 5-6 ,umol kg-1lhr-1. Again, this conversion rate was similar during the fast and fed states and was unaffected by ingestion of the arginine-free diet.
Arginine flux was lowered by giving the arginine-free diet, especially during the fed phase of the tracer study. Mean arginine intake with the arginine-rich intake during the fed state was 36 u.molkg-4hr-1. We (27) have estimated an =38% first-pass disappearance of dietary arginine within the splanchnic region; 62% of the dietary intake appears in the peripheral circulation. Assuming that this value applies to the present study, the difference between the fed-state arginine fluxes for the arginine-rich and arginine-free diets is largely, if not entirely, attributable to the :22 ,umol kg-l hr-1 (36 x 0.62) decline in the entry of dietary arginine into the circulation when the arginine-free diet was ingested. Therefore, the lower arginine flux during the fed state probably reflects quantitatively a diminished supply of dietary arginine, rather than a change in the rate of entry, into the plasma compartment, of endogenous arginine coming from tissue protein breakdown and/or de novo synthesis. The similar plasma leucine fluxes (Table 2 ) under the two arginine-intake conditions imply comparable rates of leucine, and therefore of arginine, release into plasma from the turnover of body proteins and thus supports our reasoning that the lower, fed-state arginine flux, with the arginine-free intake, is due to the altered rate of entry of dietary arginine into the peripheral circulation. However, in this same context, the -20% decrease in plasma arginine flux during the fasting state with the arginine-free diet is not as readily understood, because the leucine fluxes were also the same during this state with the two diets. It is possible that the ratio ofthe plasma leucine and arginine fluxes under different conditions is the consequence of more complex metabolic relationships rather than simply one of turnover of these amino acids from the same proteinbound amino acid pools.
From these findings, the lower, fed-state plasma arginine concentration (Table 3) indicates a reduced entry rate of dietary arginine into the circulation, and the decline in the fasting-and fed-state levels of plasma ornithine (Table 3) is probably a consequence of a reduced rate of arginine degradation, with diminished conversion to ornithine and glutamate (28). Citrulline concentrations were not affected in the fasting condition, although they rose slightly, but significantly (P < 0.05), in the fed condition when the arginine-free diet was consumed.
Under steady-state conditions, the plasma citrulline flux (Qj) of8-11 ,.mol kg-1 hr-1 ( Table 2 ) provides an index ofthe rate of formation, as weil as degradation, of citrulline. Since the metabolic disappearance (degradation) of citrulline from plasma occurs via formation of argininosuccinic acid, with subsequent synthesis of arginine, it is necessary to consider the difference found here between the plasma citrulline flux (Qj) and the estimated rate ofconversion ofisotopic citrulline to plasma arginine (Q,). The latter rate was about [5] [6] ,mol kg-l-hr-1 (Table 2) , which is essentially identical to the rate found for arginine synthesis by the kidney of hypertensive patients with normal renal function and determined from arterio-venous difference measurements across this organ (29). This synthesis occurs in the proximal convoluted tubule of the kidney (30-33). We used L- [5,5-2H2] citrulhine as the tracer, which, in theory, could be recycled through arginine and ornithine pools with return to the plasma compartment. This possibility was confirmed in our second pilot study. As shown in Table   4 , citrulline fluxes obtained with the [2H21citrulline probe were 82% (P < 0.05) of those derived with [ureido-13C] citrulline; this latter label would not be recycled, because it is lost as urea during one turn of the urea cycle. Thus, the [2H2]citrulline underestimates the actual citrulline flux, but these comparative citrulline tracer data may help to explain the metabolic basis for the difference between Qc and Qca, as follows.
First, the cycling between arginine and citrulline via the L-arginine/nitric oxide pathway (34, 35) can be ruled out as an explanation for the difference between the [13C]-and [2H]citrulline fluxes, since both of these labels would be recycled to the same extent. Second, we assume that the 5,5-2H2 label of citrulline is not recycled via direct flow through the plasma arginine pool, because only a low level of plasma arginine labeling was achieved by giving the citrulline tracer. Thus, part of the labeled citrulline appears to be taken up and converted to arginine at a metabolic site(s) which is separated from the plasma arginine pool and does not equilibrate with it. Subsequently, this plasma-citrulline-derived arginine is metabolized to ornithine and then to citrulline, which reappears as the 5,5-2H2 compound in plasma. Third, it is assumed that there are no other significant routes of loss of plasma citrulline other than via the flow from citrulline to Arg-free 10.6 ± 3.2 9.7 ± 2.7 49.0 ± 7.5t 47.5 ± 8.8t 5.2 ± 1.3 5.7 ± 1.3 107 ± 15 143 ± 10* Values are ,umol kg-l-hr-1 (mean ± SD, n = 5).
*Significantly (P < 0.05) higher than for the fasting state. tSignificantly (P < 0.05) lower than for the arginine-rich diet. (, umol/liter, mean ± SD, n = 5) are for samples taken at the end of the first 3 hr (fast) and at the end of the 5-hr fed phase of the 8-hr tracer infusion. *Different (P < 0.05) from fast. tDifferent (P < 0.05) from arginine-rich. ornithine (Q,.O, involving an inaccessible arginine pool and an "ornithine site") and via the conversion of plasma citrulline to arginine (Q.a) in the kidney.
Based on these considerations, tracer/tracee mass balance equations were developed and further details of the model will be provided upon request. Applying these equations to our dietary conditions, we arrive at the following interpretation of our data. If we assume a 20% recycling of the [2H2Jcitrulline label, the nonrecycling flux, which equals the rate of citrulline production (appearance) via this cycle (Qo-c), is =12 Smol"kg-l hr-1. Of this, 5.5 ,umol kg-l hr-1 is converted to arginine that appears in plasma. This latter conversion rate (Qca) is estimated from the 2H2 enrichments of citrulline and arginine and a simultaneous infusion of guanidino-labeled arginine, analogous to determination ofthe plasma phenylalanine-to-tyrosine conversion rate proposed by Clarke and Bier (25) . This plasma citrulline-to-arginine conversion (Qca) equals the net citrulline production (Qo-c -Qo). A large fraction of the flow from plasma citrulline back to ornithine then leaves the system, probably via conversion to glutamate, and about 2.4 ,umol-kg-lhr-1 is recycled. Correcting the total citrulline production rate (Qoc_) for the recycling component gives the measured flux of the recycled [5,5-2H2dcitrulline . This equals 10.6 ,umolkg-1hr-1, and it reflects the recycling-corrected flow of citrulline from its site of production through the plasma site. On leaving the plasma site, part of the flow of citrulline feeds the conversion of plasma citrulline to arginine and another part flows back to ornithine (i.e., Q,O), where it then leaves the cycle, at the ornithine site. Thus, the flux of the recycling tracer is always larger than the plasma citrulline-to-arginine conversion rate alone.
Despite the complexity of these in vivo isotopic data, they are coherent; both Q, and Q,a did not change between the arginine-rich and arginine-free diets. On this basis, we conclude that the net synthesis rate of arginine was not affected by a 7-day arginine-free intake. Using a less direct tracer model approach, involving comparison of plasma arginine and leucine fluxes, we (19) concluded previously that an arginine-free intake did not affect the rate of endogenous arginine synthesis. Our observations are consistent with those of Dhanakoti et al. (31) , who found that renal arginine synthesis in the adult rat was unaffected by the intake of dietary arginine, and of Hartman and Prior (36) , who reported no change in intestinal citrulline synthesis in rats given an arginine-free, glutamate-supplemented diet.
There is a clear inter-organ and intracellular compartmentation to arginine metabolism in vivo (31, 33, 37, 38) . Our previous tracer studies (18, 19, 27) have indicated that the rapid turnover of arginine within the hepatic urea cycle is effectively isolated from the metabolism of arginine within the cytosolic free amino acid pool of the liver and from the arginine pools within the peripheral circulation and tissues. Against this background, and together with the present and previous findings (19) , we now propose that whole-body arginine homeostasis in healthy adults is achieved principally via a modulation in the level of dietary arginine intake and/or with regulation in the rate of arginine degradation; changes in the net rate of arginine synthesis in extrahepatic tissues do not appear to be an important contributor to arginine homeostasis (Fig. 1) . Consistent with this proposal is a report showing that ornithine oxidation is reduced in mice given an arginine-free diet (39). Further, our hypothesis predicts that those conditions which greatly increase the metabolic demand for arginine, such as major trauma (40, 41), severe sepsis, or marked catch-up growth (14) , would precipitate a conditional deficiency of arginine unless there was an adequate supply of arginine or citrulline available from exogenous (enteral or parenteral) sources. Also, this scheme anticipates that, in comparison with citrulline and arginine, exogenous ornithine would serve as a relatively poor substrate for maintaining body arginine balance; evidence from experimental (42, 43) clinical (14, (44) (45) (46) studies favors this suggestion.
In conclusion, the net rate of de novo arginine synthesis in human subjects appears to be unaffected by acute changes in the dietary intake level of the amino acid; evidently, arginine homeostasis is achieved by changing the rate of arginine Metabolic relationships between extrahepatic "ureacycle" arginine and its precursors, ornithine and citrulline. The heavy arrow is intended to convey the idea that arginine homeostasis is achieved via alterations in the dietary intake level of arginine and its rate of catabolism to ornithine and glutamate. The net synthesis of arginine, via conversion of ornithine to citrulline (in intestine) and of citrulline to arginine (in kidney), is assumed to be less influenced by a regulatory control. In the hepatic urea cycle: ARG, arginine; ORN, ornithine; CIT, citrulline.
5,5-2H2
10.3 ± 2.9 (81 ± 6%) 8.7 ± 1.6 (82 ± 5%)
Values (mean ± SD, n = 4) for [5,5-2H2] citrulline are significantly (P < 0.05) lower than those for [ureido-13C]citrulline.
Proc. Natl. Acad Sci. USA 90 (1993) degradation relative to the dietary intake level and metabolic state. It follows that conditions which substantially increase arginine utilization and turnover would lead to a dietary requirement for this amino acid and so this explains why, from a metabolic standpoint, it is conditionally indispensable in human nutrition.
